Suchergebnisse - "Wang, Junjie"

PubPharm (19)

1

Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2023

von Wei, S. | Wei, F. | Li, M. | +4

2

Discovery of the First Potent IDO1/IDO2 Dual Inhibitors : A Promising Strategy for Cancer Immunotherapy

enthalten in: Journal of medicinal chemistry | 2021

von He, X. | He, G. | Chu, Z. | +11

3

Design and synthesis of novel mitochondria-targeted CDDO derivatives as potential anti-cancer agents

enthalten in: Bioorganic chemistry | 2021

von Ju, W. | Li, N. | Wang, J. | +5

4

Nanoparticle-based approaches to target the lymphatic system for antitumor treatment

enthalten in: Cellular and molecular life sciences : CMLS | 2021

von Peng, X. | Wang, J. | Zhou, F. | +2

5

Incidence and prognostic factors of primary thyroid lymphoma and construction of prognostic models for post-chemotherapy and postoperative patients : a population-based study

enthalten in: BMC endocrine disorders | 2021

von Xiang, N. | Dong, F. | Zhan, X. | +4

6

Tumor-associated macrophages : potential therapeutic strategies and future prospects in cancer

enthalten in: Journal for immunotherapy of cancer | 2021

von Li, C. | Xu, X. | Wei, S. | +4

7

Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants

enthalten in: European journal of medicinal chemistry | 2020

von Wang, B. | Zhang, W. | Liu, X. | +14

8

Novel Phospholipid-Based Labrasol Nanomicelles Loaded Flavonoids for Oral Delivery with Enhanced Penetration and Anti-Brain Tumor Efficiency

enthalten in: Current drug delivery | 2020

von Wang, G. | Wang, J. | Guan, R.

9

Sorafenib attenuated the function of natural killer cells infiltrated in HCC through inhibiting ERK1/2

enthalten in: International immunopharmacology | 2019

von Li, C. | Wei, S. | Xu, X. | +4

10

Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors

enthalten in: Journal of medicinal chemistry | 2019

von Wu, Y. | Wang, B. | Wang, J. | +16